

# House of Delegates

---

## REPORT ON THE VIRTUAL HOUSE OF DELEGATES

March 14-21, 2025

---

### RESULTS OF THE VOTING

Between March 14 and 21, the ASHP House of Delegates (roster attached as an Appendix) voted on 15 policy recommendations. Delegates approved seven policy recommendations by 85% or more, the threshold for final approval. Eight policy recommendations did not receive 85% of the votes and will be sent to the June House of Delegates.

### POLICY RECOMMENDATIONS APPROVED

The seven policy recommendations **approved** are as follows (percentage of delegates voting to approve follows the policy title):

#### **Care-Commensurate Reimbursement (98.5%)**

*Source: Council on Public Policy*

To discontinue ASHP policy 2020, Care-Commensurate Reimbursement, which reads:

To advocate that reimbursement for healthcare services be commensurate with the level of care provided, based on the needs of the patient.

#### **Patient Adherence Programs as Part of Health Insurance Coverage (97.5%)**

*Source: Council on Public Policy*

To discontinue policy 1504, Patient Adherence Programs as Part of Health Insurance Coverage, which reads:

To advocate for the pharmacist's role in patient medication adherence programs that are part of health insurance plans; further,

To advocate those programs that (1) maintain the direct patient pharmacist

relationship; (2) are based on the pharmacist's knowledge of the patient's medical history, indication for the prescribed medication, and expected therapeutic outcome; (3) use a communication method desired by the patient; (4) are consistent with federal and state regulations for patient confidentiality; and (5) permit dispensing of partial fills or overfills of prescription medications in order to synchronize medication refills and aid in medication adherence.

### **Nonproprietary Naming of Biological Products (98.0%)**

*Source: Council on Public Policy*

To discontinue policy 1535, Nonproprietary Naming of Biologic Products, which reads:

To advocate that originator biological products, related biological products, and biosimilar products share the same global nonproprietary name as defined by the United States Adopted Name Council, the World Health Organization Programme on International Nonproprietary Names, and United States Pharmacopeial Convention; further,

To oppose unique nonproprietary naming for originator biological products, related biological products, and biosimilar products.

### **Employee Testing (97.0%)**

*Source: Council on Public Policy*

To discontinue policy 9108, Employee Testing, which reads:

To oppose the use of truth-verification testing such as polygraphs as routine employment practices because of the possible interference with the rights of individuals; further,

To recognize the limited use of such testing during employment where such testing may protect the rights of individuals against false witness.

### **Generic Substitution of Narrow Therapeutic Index Drugs (99.5%)**

*Source: Council on Therapeutics*

To discontinue ASHP policy 0817, Generic Substitution of Narrow Therapeutic Index Drugs, which reads:

To support the current processes used by the Food and Drug Administration (FDA) to determine bioequivalence of generic drug products, including those with a narrow therapeutic index, and to recognize the authority of the FDA to decide if additional studies are necessary to determine equivalence; further,

To oppose a blanket restriction on generic substitution for any medication or medication class without evidence from well-designed, independent studies that demonstrate inferior efficacy or safety of the generic drug product.

### **Professional Development as a Retention Tool (93.6%)**

*Source: Council on Education and Workforce Development*

To recognize that pharmacy workforce development is an essential component of staff recruitment, retention, and well-being; further,

To recognize that pharmacy workforce development encompasses more than formal education programs and includes informal learning among colleagues, mentoring, participation in activities of professional organizations, and other types of learning; further,

To encourage healthcare executives to support pharmacy workforce development programs, including leadership succession planning, as an important benefit that aids in recruiting and retaining qualified staff; further,

To support healthcare executives with pharmacy workforce development by providing educational programs, services, and resources.

To encourage organizations to assess the effectiveness of professional development initiatives by evaluating their impact on recruitment and retention outcomes.

*Note: This policy supersedes ASHP policy 2103.*

### **Pharmacy Access to Payer Networks (86.8%)**

*Source: Council on Pharmacy Management*

To oppose pharmacy access criteria that impose discriminatory requirements or qualifications on participation in insurance payer networks that interfere with patient continuity of care or patient site-of-care options; further,

To advocate for laws and regulations that require healthcare payers to disclose to pharmacies applying to participate in payer networks the criteria and the clinical and operational outcome data reporting requirements used to include, retain, or exclude pharmacies; further,

To encourage healthcare payers to standardize network access criteria and eliminate those reporting requirements already imposed by accrediting bodies or regulatory agencies.

*Note: This policy supersedes ASHP policy 2031.*

## **POLICY RECOMMENDATIONS NOT APPROVED**

The House **voted to not approve** the following eight policy recommendations (percentage of delegates voting to approve follows the policy title):

### **Safe and Secure Transfer of Controlled Substances (65.5%)**

*Source: Council on Pharmacy Practice*

To advocate for the standardization of policies, procedures, and practices in the handling of controlled substance medications throughout the care process, including transfers between emergency medical services and during interfacility transport; further,

To promote closed-loop communication processes related to controlled substance medication management during patient transfers; further,

To collaborate with emergency medical services and other stakeholders involved in pre- and post-hospital and interfacility transfers of controlled substances to improve patient safety, minimize variation, and ensure compliance.

### **Pharmacy Services to Optimize Patient Throughput (79.7%)**

*Source: Council on Pharmacy Practice*

To support the integration of pharmacy services as systems are optimized to improve health system-wide patient throughput; further,

To advocate for pharmacists to serve as key decision-makers for improving patient flow throughout the health system; further,

To develop resources related to incorporating pharmacy services into patient throughput action plans and process maps; further,

To identify measures and tracking systems that demonstrate the impact of pharmacy-driven services to optimize patient throughput.

### **Funding, Expertise, and Oversight of State Boards of Pharmacy (68.8%)**

*Source: Council on Public Policy*

To advocate appropriate oversight of pharmacy practice and the pharmaceutical supply chain through coordination and cooperation of state boards of pharmacy and other state and federal agencies whose mission it is to protect the public health; further,

To advocate representation on state boards of pharmacy and related agencies by pharmacists and pharmacy technicians; further,

To advocate that hospitals and health systems are adequately represented on state boards of pharmacy; further,

To advocate for dedicated funds for the exclusive use by state boards of pharmacy and related agencies to carry out expected duties; further,

To advocate for established training of state board of pharmacy inspectors in diverse pharmacy practice areas and the implementation of adequate inspection schedules to ensure the effective oversight and regulation of pharmacy practice, the integrity of the pharmaceutical supply chain, the protection of the public, and to establish variances from any documented rule

by the board of pharmacy; further,

To advocate that inspections be performed only by individuals with demonstrated competency in the applicable area of practice.

*Note: This policy would supersede ASHP policy 2021.*

### **Pharmacists Cross-State Licensure (81.8%)**

*Source: Council on Public Policy*

To advocate that state boards of pharmacy collaborate to streamline the licensure process through standardization and improve the timeliness of application approval across state lines; further,

To advocate that state boards of pharmacy collaborate with third-party vendors to streamline the licensure transfer or reciprocity process; further,

To advocate that boards of pharmacy grant licensed pharmacists in good standing temporary licensure, permitting them to engage in practice, while their application for licensure transfer or reciprocity is being processed.

*Note: This policy would supersede ASHP policy 1621.*

### **Clinical and Safety Considerations of Naming Drug Moieties and Complexes (71.5%)**

*Source: Council on Therapeutics*

To oppose the consolidation of existing drug classes that include drugs that have distinct pharmacologic effects and pharmacokinetic/pharmacodynamic profiles; further,

To encourage regulatory agencies to consider clinical, operational, access, and safety factors when approving and classifying medications with different moieties or complexes that are used to deliver the active drug; further,

To advocate for the pharmacist's active role in these processes; further, to foster increased pharmacist, provider, and public awareness when changes in approved drug products with therapeutic equivalence occur.

### **Clinical, Operational, and Safe Use of Manipulated Drug Products and Alternate Administration Routes (64.2%)**

*Source: Council on Therapeutics*

To support clinically appropriate, evidence-based use of manipulated drug-products or alternate drug administration routes when it supports optimal patient care; further,

To promote research that further delineates the pharmacokinetic and pharmacodynamic properties of drugs when manipulated or when given through alternate administration routes and investigate the interrelationship between drug exposure and safety and efficacy outcomes

including the potential role of artificial intelligence in advancing model development and validation; further,

To encourage manufacturers to develop drug products in ready-to-use devices and diverse formulations; further,

To foster pharmacist-led interdisciplinary teams to provide institutional guidance, best practices, and safety recommendations regarding drug products that are manipulated or administered through alternative routes.

*Note: This policy would supersede ASHP policies 2041, 2242, and 2314.*

### **Expedited Partner Directed Therapy (78.8%)**

*Source: Council on Therapeutics*

To affirm that the pharmacy workforce improves patient access to therapies that prevent and treat sexually transmitted infections in all settings; further,

To support legislation that promotes expedited partner therapy (EPT); further,

To affirm that interpreting test results, prescribing, dosing, and dispensing therapies as clinically indicated is within pharmacists' scope of practice; further,

To affirm that drug products for EPT should be provided to individuals in a manner that ensures safe and appropriate use; further,

To encourage surveillance of EPT as a public health effort.

### **Recovery and Assistance Programs for Healthcare Workers with Substance Use Disorder (51.7%)**

*Source: Council on Pharmacy Management*

To advocate that hospitals and health systems establish recovery and assistance programs for healthcare workers with substance use disorders, including those who have diverted controlled substances to support their own drug addiction; further,

To encourage state licensing boards to support structured rehabilitation programs that demonstrate a clear pathway for recovery and return to practice upon successful completion of the program.

## **NOTES ON VOTING**

91 percent (211) of delegates to the virtual House of Delegates participated in the voting.

## ASHP HOUSE OF DELEGATES

Jesse H. Hogue, Chair  
Nishaminy Kasbekar, Vice Chair

As of March 14, 2025

OFFICERS AND BOARD OF DIRECTORS			
Leigh A. Briscoe-Dwyer, President			
Melanie A. Dodd, President-Elect			
Nishaminy Kasbekar, Immediate Past President			
Christene M. Jolowsky, Treasurer			
Paul W. Abramowitz, Chief Executive Officer			
Kristine K. Gullickson, Board Liaison, Council on Public Policy			
Jesse H. Hogue, Chair of the House			
Vivian Bradley Johnson, Board Liaison, Council on Pharmacy Management			
Dawn M. Moore, Board Liaison, Commission on Affiliate Relations			
Vickie L. Powell, Board Liaison, Council on Pharmacy Practice			
Douglas C. Slain, Board Liaison, Council on Therapeutics			
Jennifer E. Tryon, Board Liaison, Council on Education and Workforce Development			
PAST PRESIDENTS			
Roger Anderson	Fred Eckel	Lynnae Mahaney	Thomas Thielke
John Armitstead	Rebecca Finley	Gerald Meyer	Linda Tyler
Daniel Ashby	Lisa Gersema	John Murphy	Paul Walker
Jill Martin Boone	Diane Ginsburg	Cynthia Raehl	T. Mark Woods
Cynthia Brennan	Harold Godwin	Philip Schneider	David Zilz
Paul Bush	Mick Hunt	Kathryn Schultz	
Bruce Canaday	Clifford Hynniman	Bruce Scott	
Jannet Carmichael	Marianne Ivey	Steven Sheaffer	
Kevin Colgan	Thomas Johnson	Janet Silvester	
Debra Devereaux	Stan Kent	Kelly Smith	
STATE	DELEGATES		ALTERNATES
<b>Alabama (3)</b>	Nancy Bailey Danna Nelson Sarah Blackwell		Laura Matthews
<b>Alaska (2)</b>	Shawna King Karina Rauenhorst Stark		Aly Noble
<b>Arizona (3)</b>	Christopher Edwards Kelly Erdos Mary Manning		Janelle Duran Jake Schwarz Sarah Stephens
<b>Arkansas (3)</b>	Jamalee Huntley Phillip Jackson Kim Young		Brandy Hubbard

<b>California (7)</b>	Gary Besinque Katrina Derry Emily Do Jaclyn Jaskowiak Elaine Law Stacey Raff Caroline Sierra	Steve Gray Keith Yoshizuka
<b>Colorado (3)</b>	Lance Ray Tara Vlasimsky Bridger Singer	Ashley Ramp
<b>Connecticut (3)</b>	Sam Abdelghany Shannon Giddens Colleen Teevan	Chandra Cooper Jason Zybert
<b>Delaware (2)</b>	Cheri Briggs Pooja Dogra	
<b>Florida (6)</b>	Madeline Camejo Venessa Goodnow Dave Lacknauth Dionis Malo Heather Petrie Elaina Rosario	Luis Alfonso Jessica Bianco
<b>Georgia (3)</b>	Davey Legendre Meredith Lopez Samantha Roberts	Darren Evans Derek Gaul
<b>Hawaii (2)</b>	Shelley Kikuchi Mark Mierzwa	
<b>Idaho (2)</b>	Paul Driver Victoria Wallace	
<b>Illinois (5)</b>	Megan Corrigan Andy Donnelly Bernice Man Jennifer Phillips Matthew Rim	Chris Crank Jim Dorociak Sharon Karina Jason Orr Samantha Rimas
<b>Indiana (3)</b>	Rachael Kruer Andrew Lodolo Tate Trujillo	Jennifer Reiter
<b>Iowa (3)</b>	John Hamiel Jessica Nesheim Arinze Nkemdirim Okere	Jennifer Williams
<b>Kansas (3)</b>	Christina Crowley Megan Ohrlund Katie Wilson	Matt Bilhimer Jeff Little
<b>Kentucky (3)</b>	Dale English Scott Hayes Elizabeth Schlosser	Brandy Brown Rachel Swope



<b>Louisiana (3)</b>	Neil Hunter Heather Maturin Heather Savage	Myra Thomas Renesha Yarbrough
<b>Maine (2)</b>	Brian McCullough	
<b>Maryland (4)</b>	Justin Hare John Hill Terri Jorgenson Molly Wascher	Courtney Henry Marybeth Kazanas
<b>Massachusetts (4)</b>	Erica Housman Jason Lancaster Frankie Mernick Russel Roberts	Marla O'Shea-Bulman
<b>Michigan (4)</b>	Rox Gatia Lama Hsaiky Amber Lanae Martirossov Rebecca Maynard	Jessica Jones Ed Szandzik
<b>Minnesota (3)</b>	Lance Oyen Rachel Root Cassie Schmitt	Benjamin Anderson Ryan Hannan Paul Morales
<b>Mississippi (2)</b>	Joshua Fleming Andrew Mays	Wesley Pitts
<b>Missouri (3)</b>	Tony Huke Amy Sipe Mel Smith	Zach Gunter Cassie Heffern Sayo Weihs
<b>Montana (2)</b>	JoEllen Maurer Logan Tinsen	
<b>Nebraska (3)</b>	Fred Massoomi Katie Reisbig David Schmidt	Jolyn Merry
<b>Nevada (2)</b>	Adam Porath Judy Mattorano	Kate Ward
<b>New Hampshire (2)</b>	Melanie McGuire Marilyn Hill	Jessica Marx
<b>New Jersey (4)</b>	Rich Artymowicz Julie Kalabalik-Hoganson Deb Sadowski Craig Sastic	Barbara Giacomelli Agnieszka Pasternak Jennifer Sternbach
<b>New Mexico (2)</b>	Nick Crozier John Rafi	
<b>New York (5)</b>	Amisha Arya Charrai Byrd Nicole Cieri Hutcherson Travis Dick Leila Tibi-Scherl	Paul Green Russ Lazzaro Michael Ott Sammy Yafai

<b>North Carolina (4)</b>	Leslie Barefoot Nick Gazda Jeffrey Reichard Andy Warren	Tyler Vest
<b>North Dakota (2)</b>	Maari Loy Saidee Oberlander	Katie Evans
<b>Ohio (5)</b>	Ashley Duty Indrani Kar Julie Kennerly-Shah Cynthia King Dan Lewis	Beth Krause Joshua Musch
<b>Oklahoma (3)</b>	Christopher Pack Deidra Williams Jimmy Williams	
<b>Oregon (3)</b>	Michael Lanning Edward Saito Ryan Wargo	Kristy Butler Stacey Olstad
<b>Pennsylvania (4)</b>	Scott Bolesta Lauren Finoli Arpit Mehta Cassandra Redmond	Jennifer Belavic Sejal Patel-Francis Jill Rebuck Joseph Stavish Evan Williams
<b>Puerto Rico (2)</b>	Carlos Méndez Bauza Idaliz Rodriguez Escudero	Mirza Martínez Giselle Rivera
<b>Rhode Island (2)</b>	Nelson Caetano Karen Nolan	Martha Roberts
<b>South Carolina (3)</b>	Thomas Achey Lisa Gibbs Sarah Steinert	Reagan Barfield
<b>South Dakota (2)</b>	Betsy Karli Laura Stoeber	Anne Morstad Ryan Waybright
<b>Tennessee (4)</b>	Don Branam Justin Griner Grayson Peek Jennifer Robertson	Meredith Gilbert Erin Neal
<b>Texas (6)</b>	Joshua Blackwell Linda Haines Phuoc Anne Nguyen Binita Patel Aaron Reich Jeffrey Wagner	Bradi Frei Stephanie Stramel
<b>Utah (3)</b>	Conor Hanrahan Shannon Inglet Krystal Moorman-Bishir	
<b>Vermont (2)</b>	Stacey Dalpoas Kevin Marvin	Jennifer Burrier Emily Piehl

<b>Virginia (4)</b>	Matt Jenkins Kathy Koehl Amy Schultz Rodney Stiltner	Ian Orensky
<b>Washington, D.C. (2)</b>	Sue Carr Kelly Mullican	Joann Lee
<b>Washington State (3)</b>	Chris Greer Laura Hanson Karen White	Kevin Anderson
<b>West Virginia (2)</b>	Chris Fitzpatrick Derek Grimm	
<b>Wisconsin (4)</b>	Monica Bogenschutz Matt Carleton John Muchka Sarah Peppard	Girish Kaimal David Reeb Terri Wallner Jordan Wulz
<b>Wyoming (2)</b>	Jonathan Beattie Channa Richardson	
<b>SECTIONS AND FORUMS</b>	<b>DELEGATES</b>	<b>ALTERNATES</b>
<b>Ambulatory Care Practitioners</b>	Sara Panella	Ashley Parrott
<b>Clinical Specialists and Scientists</b>	Megan Musselman	Angela Colella
<b>Community Pharmacy Practitioners</b>	Courtney Isom	Amanda Place
<b>Digital and Telehealth Practitioners</b>	Lisa Stump	
<b>Inpatient Care Practitioners</b>	Lucas Schulz	Molly Billstein Leber
<b>Pharmacy Educators</b>	Jennifer Arnoldi	Tim Brown
<b>Pharmacy Informatics and Technology</b>	Jeffrey Chalmers	David Agüero
<b>Pharmacy Practice Leaders</b>	Katherine Miller	Anthony Scott
<b>Specialty Pharmacy Practitioners</b>	Erica Diamantides	Karen Thomas
<b>New Practitioners Forum</b>	Alfred Awuah	Luning Shi
<b>Pharmacy Student Forum</b>	Katy Xia	
<b>The Pharmacy Technician Society</b>	Daniel Nyakundi	
<b>FRATERNAL</b>	<b>DELEGATES</b>	<b>ALTERNATES</b>
<b>U.S. Air Force</b>	Elizabeth Tesch	Rohin Kasudia
<b>U.S. Army</b>	Daniel Zsido	Gregory Hare
<b>U.S. Navy</b>	Terence Cusack	Chirag Patel
<b>U.S. Public Health Service</b>	Russ Gunter	Jeffrey Gildow Chenoa Shelton
<b>Veterans Affairs</b>	Julie Groppi	Heather Ourth